Skip to main content

Welcome to mRNA Access

Leveraging the Power of mRNA for Global Health

At Moderna, we are grounded in the belief that mRNA is transformational. And, for us, our COVID-19 vaccine Spikevax® is just the beginning.

Our mRNA platform, with its speed, scale, and flexibility, is uniquely suited to tackle current and emerging pathogens that threaten global health.

mRNA Access, powered by Moderna, invites you to be part of what comes next.

Home Hero mRNA Access Logo
Microscope Image
What we do

Our Mission

mRNA Access aims to accelerate the creation of new vaccines using mRNA technology in collaboration with global partners.

Through the program, researchers beyond Moderna can take advantage of the flexibility afforded by our platform to develop novel mRNA medicines for emerging and neglected infectious diseases.

At Moderna, we understand that the COVID-19 pandemic will not be our last. And our mission is to support scientists around the world as they work to protect our global health.

What we provide

mRNA Access Partnership Benefits

mRNA Access invites you to partner with us to explore the possibility of mRNA for the benefit of global health.

Moderna has spent a decade developing our mRNA platform to advance mRNA medicines. Our iterative vaccine design approach to emerging infectious disease like SARS-CoV-1 and MERS enabled our COVID-19 vaccine and allowed us to realize the potential of our platform to positively impact the lives of hundreds of millions of people. 

Through mRNA Access, we invite researchers around the world to design novel vaccines against emerging and neglected infectious diseases, and, with the support of Moderna, leverage our platform to advance vaccines through pre-clinical development.

Researchers who join the collaborative model will have access to our platform and support from our research teams.

products-banner-image-desktop
Featured Resources
Video

Moderna Seminar Series. Chapter 1: Intro to mRNA Medicine

  • February 9, 2022
  • 22:41
Webinar Series
hp-banner-video-mobile
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
Journal Article

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

  • August 1, 2020
  • Nature
mRNA Vaccines
Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs From Ebola Virus Disease
Journal Article

Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs From Ebola Virus Disease

  • November 30, 2017
  • Journal of Infectious Diseases
Preclinical
Protective Efficacy of Nucleic Acid Vaccines Against Transmission of Zika Virus During Pregnancy in Mice
Journal Article

Protective Efficacy of Nucleic Acid Vaccines Against Transmission of Zika Virus During Pregnancy in Mice

  • July 1, 2019
  • Journal of Infectious Diseases
Preclinical
Video

Moderna Seminar Series. Chapter 2: Basic mRNA Biology

  • February 9, 2022
  • 12:39
Webinar Series
Melissa Moore Webinar Chapter 2

Interested in mRNA Access?

Partner with us to bring this global health initiative to life.

By submitting your information, you agree to Moderna’s Terms and Conditions. You also acknowledge that your information will be processed in accordance with Moderna’s Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Services apply.